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1. INTRODUCTION
Thyroid hormones exert several profound effects on the cardiovascular system. These effects can be
studied in patients with differentiated thyroid cancer (DTC) who are treated with the combination of total
thyroidectomy and radioidine ablative therapy. As part of the treatment, some of these patients are kept in the
state of subclinical hyperthyroidism. As part of their follow up, lifelong thyroxin (T4) therapy is interrupted
by a short period of hypothyroidism yearly to measure thyroglobulin, the tumor marker of DTC.
Subclinical hyperthyroidism is associated with higher heart rate, frequent atrial premature beats, and
increased prevalence of atrial fibrillation. Increased left ventricular mass (LVM) and diastolic dysfunction
have  also been  reported in  subclinical  hyperthyroidism.  Changes of  the  cardiovascular  system are  well
characterized in  hypothyroidism:  bradycardia,  prolongation and increased dispersion of  the  QT interval,
increased  blood  pressure,  particularly  diastolic  pressure,  increased  periferial  vascular  resistance  with  a
reduced  cardiac  output,  and  left  ventricular  diastolic  dysfunction.  Overt  hypothyroidism  is  related  to
coronary artery disease because of atherogen lipid profile, hypertension, hyperhomocysteinemia, elevated C-
reactive protein levels, coagulation factor abnormalities, and endothelial dysfunction.
Endothelial dysfunction may initiate atherosclerosis; the detection of early atherosclerotic changes can
contribute to the prevention of cardiovascular diseases. Measuring flow-mediated dilatation (FMD) is widely
accepted for non-invasive evaluation of endothelial function. High-resolution ultrasound is used to measure
changes  in  arterial  diameter  in  response  to  reactive  hyperaemia  (endothelium-dependent  flow-mediated
vasodilatation).  Nitrogen  oxid  (NO)  plays  a  key role  in  vascular  endothelial-mediated  relaxation.  The
reduced  endothel  function,  determined  by  FMD,  is  known  to  improve  with  thyroxin  therapy  in  both
subclinical and overt hypothyroidism.
One of the recently described tools for determining cardiovascular risk is arterial wall stiffness, which
is an independent predictor of cardiac events via several mechanisms. Increased cardiac afterload, impaired
coronary  blood  flow,  direct  atherogenic  action  and microvascular  damage  may  be  contributing  factors.
Arterial stiffness can be calculated from the aortic diameter and blood pressure measured simultaneously or
can be determined by pulse wave analysis. Central arterial stiffness is reduced in untreated hyperthyroidism
based on analysis of the central arterial pressure waveform. Increased total arterial stiffness has been reported
in  overt  hyperthyroidism  using  echocardiography.  Antithyroid  drug  therapy  significantly  reduced  the
stiffness of the common carotid artery in patients with Graves’ disease. Overt and subclinical hypothyroid
subjects have increased arterial stiffness; this is reversible by thyroxin replacement. Aortic stiffness has not
been measured in subclinical hyperthyroidism.
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2. AIMS
We aimed to examine endothelial and vascular wall function by 
(1) FMD as the possible earliest marker of atherosclerosis
(2) aortic stiffness 
(3) left ventricular systolic and diastolic functions 
(4) haemostatic parameters 
(5) metabolic parameters and 
(6) markers of vascular injury 
in patients with DTC who are on TSH suppressive doses of T4, as well as after 4 weeks of T4 withdrawal, in
order to assess the cardiovascular impact of both long-term subclinical hyperthyroidism and iatrogenic short-
term hypothyroidism. 
We aimed to address the following questions:
1. Is  the  endothelial  function  measured  by  FMD  in  the  brachial  artery  altered  in  subclinical
hyperthyroidism and/or overt hypothyroidism? 
2. Is the possible alteration of the endothelial function mediated by NO? 
3. Is the aortic stiffness altered in subclinical hyperthyroidism and/or overt hypothyroidism? 
4. Is the left ventricular systolic and diastolic function altered?
5.  How does the lipid- and metabolic parameterese change in subclinical hyperthyroidism and/or overt
hypothyroidism? 6. 
6. How  do  the  recently  identified  atherosclerosis  risk  factors  (homocystein,  C-reactive  protein,
fibrinogén, von Willebrand faktor) interact with the tested functions of the vascular wall?
3. PATIENTS AND METHODS
3.1. Patients
Twenty four women (mean age 42.4±8.07 years) who had had total or near-total thyroidectomy for
DTC  were  included  in  the  study.  Patients  with  known  ischemic  heart  disease,  stroke,  cardiac  failure,
hypertension,  diabetes  mellitus,  renal  or  liver  failure,  other  systemic  or  malignant  diseases  (other  than
thyroid cancer) were excluded from the study. In 21/24 cases, 131I ablation was also performed. Three of the
24 patients declined the recommended  131I treatment. All patients were classified as “high or intermediate
risk” of DTC recurrence on the basis of the American Thyroid Assotiation (ATA) and European Thyroid
Assotiation  (ETA)  guidelines,  hence  all  had  been  on  TSH-suppressive  therapy  continuously  for  30±21
(mean±SD) weeks and were taking no other medications (TSH 0.24±0.11 mU/L). Their yearly follow up
included TSH stimulated serum thyroglobulin (Tg) level (achieved by 4 weeks thyroxin withdrawal), anti-Tg
antibodies  (aTg),  neck  ultrasonography  and,  if  indicated,  whole-body  radioiodine  scan.  The  first  Tg
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measurment was at  least 6 month after  131I treatment in parallel  with aTg. Four of 24 patients were Tg
positive (Tg > 2 ug/L); in these patients, whole-body scan (WBS) was performed. WBS was positive in 3 of
them due to small thyroid remnant and 131I ablation was repeated. One Tg postive, WBS negativ patient was
followed and consequent Tg measurments were negative. Another 3 patients were Tg negativ, aTg positive. 
Twenty two healthy volunteers, matched for age, served as euthyroid controls (TSH: 1,64±1,05 mU/l).
The same criteria were used in control subject selection, except that they had had no history of thyroid
disease. They were not taking any medication known to influence thyroid and/or cardiac function. All study
subjects gave written informed consent.
3.2 Methods
Patients were studied on the day before T4 withdrawal (subclinical hyperthyroidism) and four weeks
later,  before readministration of T4 (hypothyroidism). Controls were evaluated only once. Blood samples
were collected between 08.00-09.00 a.m. after an overnight fast for determination of TSH, free thyroxin
(fT4), free triiodothyronin (fT3), thyroglobulin, cholesterol, triglyceride, low-densitiy lipoprotein cholesterol
(LDL-C), high-densitiy lipoprotein cholesterol (HDL-C), total homocystine (Hcys), C-reactiv protein (CRP),
fibrinogen and von Willebrand factor activity (vWF). Blood pressure was measured and body mass index
(BMI) calculated. FMD and NMD were measured only in DTC patients in a self-controlled study. Results of
echocardiography  measurments  were  compared  with  healthy  controlls.  FMD  and  echocardiographic
measurements were carried out by two independent investigators who were unaware of the patients' clinical
data.
3.2.1. Biochemical measurements
TSH, fT4, fT3, Tg, aTg, cholesterol, triglyceride, LDL-C, HDL-C, Hcys, CRP, fibrinogen and vWF
were measured by commercially available assays according to the manufacturers’ recommendations.
NO synthesis  was  determined  by  measuring  the  metabolites  of  nitric  oxide,  NO2   and  NO3. For
determination of NO2+NO3, proteins were precipitated from plasma (0.5 ml) by 100 μl of 35 % sulfosalycylic
acid and samples were centrifuged in an Eppendorf centrifuge (10 min, 10 000 g). 0.4 ml of protein free
plasma was inserted into a syringe containing Cu-platted cadmium granules. The NO3 was reduced to NO2 in
the  syringe,  and  0.3  ml  of  sample  was  mixed  with  0.3  ml  of  Griess  reagent  (1  part  of  0.1  %  of
naphthylethylendiamide and 1 part of 1 % sulfanilamide), and was incubated at 60 C in water bath for 20
min. The absorbance of samples was determined in a spectrophotometer (Hewlett Packard 8453) at 546 nm.
Calibration  curve  was  prepared  using  analytical  grade  of  NaNO2,  and  was  used  for  determination  of
NO2+NO3 in plasma samples.
3.2.2 Flow-mediated (FMD) and nitrate-mediated (NMD) dilatation
Vascular studies of the brachial artery were performed non-invasively. High-resolution ultrasound was
used to measure changes in arterial diameter in response to reactive hyperaemia (endothelium-dependent,
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flow-mediated vasodilatation) as well as to glyceryltrinitrate (NTG, an endothelium-independent vasodilator)
with a 7.0 MHz linear array transducer on a Philips HDI-5000 system (Philips Medical Systems, USA).
FMD and endothelium-independent vasodilatation were assessed by measuring the percent change in the
brachial artery diameter during reactive hyperaemia and after NTG.
3.2.3 Aortic strain and stiffness
Transthoracic echocardiography was performed by using Philips HDI-5000 system (Philips Medical
Systems, Bothell, USA) 2.5 Mhz-probe at the left lateral decubitus position in a standard manner. M mode
tracings  of  the  ascending  aorta  were  obtained  in  the  parasternal  long  axis  views.  From  the  M  mode
recordings,  aortic systolic and diastolic diameters (Aos and Aod, respectively) were measured.  Aos was
determined at the time of the full opening of the aortic valve and Aod was determined at the peak of QRS.
Simultaneously, cuff brachial artery systolic (SBP) and diastolic (DBP) blood pressures were measured and
recorded. The aortic elasticity parameters, the aortic strain and aortic stiffness indexis were calculated using
the following formulas:
Aortic Strain (%) = 100 × (Aos - Aod) / Aod. 
Aortic Stiffness Index [beta] = ln (SBP/DBP) / Aortic Strain
3.2.4. Left ventricular dimensions
M-mode measurements of LV internal dimensions in diastole (LVDD) and systole (LVDS), and end-
diastolic posterior wall (PW) and interventricular septum (IVS) thicknesses and left atrium anteroposterior
diameter were obtained using the standard technique. LV fractional shortening, a measure of the percent
change in LV dimensions with systole, was calculated. 
LVM  was  corrected  for  body  surface  area  to  obtain  LVM  index  (LVMI).  Two  dimensional  left
ventricular ejection fraction (LVEF) was also aquired by the summation method. 
3.2.4. Diastolic function
The peak early transmitral filling velocity during early diastole (E), peak transmitral atrial filling velocity
during  late  diastole  (A),  and  E/A  ratio  were  used  as  left  ventricular  diastolic  function  parameters.
Quantitative diastolic data were derived from TDI data. The sample volume (4 mm3) was placed in the LV
basal portion of anterior, inferior, septal and lateral walls (using the 2- and 4-chamber images) The following
parameters (mean values calculated from three consecutive beats) were derived: early diastolic velocity (e’),
late diastolic velocity (a’), e’/a’ and E/e’ ratio. Parameters of the patient groups were compared to controls.
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3.2.6. Statistical analysis
All statistical analyses were performed by using the SAS for Windows (8.2 cary/nc SAS® Institute Inc.
USA)  statistical  package.  Continuous  data  were  expressed  as  mean±standard  deviation.  Relationships
between  the  continuous  variables  were  evaluated  by  Pearson’s  or  Spearman’s
correlation analysis. Comparisons  between  control,  subclinical  hyperthyroid  and  hypothyroid  groups  for
continuous variables were made by one way ANOVA and post-hoc Tukey’s test. To improve the normality of
the data distribution, triglyceride values were log-transformed for analysis. Simple linear regression analysis
was performed to asses the relationship between changes of aortic stiffness, FMD and other parameters. To
investigate  the  independent  effect  of  the  different  factors  on  changes  of  stiffness  and FMD,  a  multiple
stepwise linear regression model was used.  The multivariate model consisted of the changes of stiffness
index and FMD as dependent variable, and independent variables that had had significant correlation with
changes  of  stiffness  index  and  FMD in  the  simple  linear  regression  analysis.   p<0.05  was  considered
statistically significant.
4. RESULTS
4.1 Changes in humoral parameters
In subclinical hyperthyroidism, the mean TSH level was 0.24 ± 0.11 mU /L while the fT3 and  fT4
levels  were  within  the  normal  ranges  (4.79  ±  0.46  and  18.39  ±  2.33  pmol/L,  respectively).  After
discontinuation of T4 for 4 weeks, all 24 subjects achieved a hypothyroid state, as evidenced by TSH levels
(89.8 ± 29.36 mU/L) and low serum fT4 and fT3. 
Blood pressure and BMI were not significantly different in hypothyroidism compared to subclinical
hyperthyroidism and euthyroid state.
Cholesterol  (7.43±1.23 vs 4.75±1.14 mmol/L), triglyceride  (7.43±1.23 vs 4.75±1.14 mmol/L), and
LDL-C (4.55±1.1 vs. 2.7±0.89 mmol/L) increased in hypothyroidism significantly compared to subclinical
hyperthyroidism. Hcys was significantly higher in the hypothyroid state than in subclinical hyperthyroidism
(12.95±4.49 vs.  9.62±2.29 umol/L) and was the lowest in euthyroid controls  (8.67±0.87 umol/L). Mean
HDL-C  levels  were  unchanged.  Average  CRP levels  exceeded  1.0  mg/L in  both  hypothyroidism  and
subclinical hyperthyroidism (low cardiovascular risk: < 1.0 mg/L). However, CRP values were significantly
higher  in  subclinical  hyperthyroidism  than  in  hypothyroidism  (5.55±5.15  vs.  4.39±5.16  mg/L). The
fibrinogen (4.01±0.84 vs. 3.23±0.50 g/L) and vWF values (130.63±29.97 vs. 90.09±25.92 %) were higher in
subclinical hyperthyroidism, although the mean value of vWF remained within the reference range. 
4.2 Vascular parameters
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In hypothyroidism, FMD was lower than in subclinical hyperthyroidism (6.79±4.44 vs. 14.37±8.33
%),  whereas  the  vasodilatation  in  response  to  NTG was  not  different.  The  NO values  were  higher  in
subclinical hyperthyroidism than in hypothyroidism (32.34±7.0 umol/L vs. 24.56±6.71 umol/L). 
4.3 Aortic strain and stiffness
Aortic  stiffness  increased  significantly  in  both  the  hypothyroid  (6.04±2.55)  and  subclinical
hyperthyroid (9.27±4.81) groups compared to  controls  (3.92±1.84).  However,  in  hypothyroidism,  values
falling between the subclinical  hyperthyroid and control  groups were observed.  The difference in aortic
stiffness was also significant between subclinical hyperthyroidism and overt hypothroidism.
4.4 LV dimensions
As far as LV dimensions and ejection fraction are concerned, no significant changes were observed in
M-mode measurrments (LVEDD, LVESD, IVS, PW and fractional shortening) and in the two dimensional
study (LVM, LVMI and LVEF) either during T4 withdrawal, or when compared with healthy controls.
4.5 Diastolic function
Diastolic  function  parameters,  E-,  A-,  e’-  waves  were  significantly  lower  in  both  subclinical
hyperthyroidism (60.30±10.53 cm/s vs. 72.12±7.23 cm/s; 43.75±9.37 cm/s vs. 45.23±4.67 cm/s; 5.52±0.89
cm/s vs. 5.96±1.23 cm/s) and overt hypothyroidism (62.98±9.76 cm/s vs. 72.12±7.23 cm/s; 42.71±7.78 cm/s
vs.  45.23±4.67  cm/s;  5.78±1.02  cm/s  vs.  5.96±1.23  cm/s)  compared  to  healthy  controls.   a’-wave  was
significantly higher in the two hormonal abnormalities compared to controls  (5.48±0.9 cm/s vs. 4.45±1.34
cm/s; 5.08±1.11 cm/s vs. 4.45±1.34 cm/s). The E/A (1.47±3.67 cm/s vs. 1.59±3.67 cm/s;  1.37±4.16 cm/s vs.
1.59±3.67 cm/s)  and e'/a'  (1.13±0.98 cm/s vs.  1.34±1.02 cm/s;  1.0±0.14 cm/s vs.  1.34±1.02 cm/s) were
significantly  lower  in  subclinical  hyperthyroidism.  E/e’ was  higher  in  subclinical  hyperthyroidism  and
hypothyroidism, than control (10.99±1,7 vs 9.85±2.28; 10.47±1.0 vs 9.85±2.28). Heart rate was lower in
hypothyroidism and higher in subclinical hyperthyroidism (70.6±6,78 beats/min. vs. 78.35±7,23 beats/min).
4.6 Correlation between changes in aortic stiffness and laboratory parameters
By simple  regression  analysis,  changes  of  FMD  while  on  T4 suppressive  therapy correlated  in  a
positive  manner  with  changes  of  NO (r=0.67,  p=0.0006),  as  well  as  with  vWF (r=0.54,  p=0.005)  and
fibrinogen (r=0.45, p=0.01) levels. There was no significant correlation between LDL-C and FMD. Changes
in fT3, fT4, and TSH on T4suppressive therapy did not significantly correlate with changes of  FMD (FMD
vs. fT3 r=-0.14, P=0.56, FMD vs fT4 r=-0.18, P=0.48, FMD vs TSH r=-0.17, p=0.52) or with changes in vWF
(vWF vs. fT3 r=-0.21, P=0.55, vWF vs. fT4 r=-0.24, p=0.21, vWF vs. TSH r=-0.03, P=0.78), or NO (NO vs.
fT3 r=-0.11, P=0.67, NO vs fT4 r=-0.13, p=0.45, NO vs TSH r=-0.21, p=0.21). 
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Stepwise multiple regression analysis of changes in various clinical variables in the patients on  T4
suppressiv therapy included changes of NO, vWF, fibrinogen,  fT4 and LDL-C. Only NO and fibrinogen
emerged as independent factors associated in a positive manner with FMD change.
By simple regression analysis,  changes of aortic stiffness index during transition from subclinical
hyperthyroidism to hypothyroidism correlated with changes of vWF (r=0.61, p=0.013), fT4 (r=0.65, p=0.01)
and fibrinogen (r=0.51, p=0.01) in a positive manner, while with LDL-C in a negative manner (r= - 0.49,
p=0.01). 
Stepwise multiple  regression analysis  is  included aortic  stiffness  index,  vWF,  fibrinogen,  fT4 and
LDL-C;  only vWF and fT4 emerged as  independent  factors  associated in  a positive  manner  with aortic
stiffness.
5. DISCUSSION
The  aim  of  this  study  was  to  compare  the  cardiovascular  effects  of  long-term  subclinical
hyperthyroidism and short-term overt hypothyroidism. These hormonal states are part of the therapy and
follow-up of DTC patients: subclinical hyperthyroidism is aimed to keep TSH, a known groth factor in DTC,
in the low or unmeasurable range, while T4 treatment is withdrawn for 4 weeks once a year to achieve TSH
stimulation of thyroglobulin synthesis, the tumor marker in DTC.   
In  the  present  study  we  examined  endothelial  function  together  with  NO,  aortic  stiffness,  left
ventricular  systolic and diastolic functions,  metabolic parameters and hemostatic factors in patients with
DTC who were on TSH-suppressive doses of T4, as well as after 4 weeks of T4 withdrawal. In our study we
focused  on  a  selected  series  of  patients  without  known  atherosclerotic  diseases  and  risk  factors.  The
parameters were compared in a self-controled study, while echocardiography results were compared with
healthy controls.
In subclinical hyperthyroidism, the FMD and NO was markedly higher and lipid profile was better
than  in  hypothyroidism.  The  constellation  of  the  parameters  measured  predisposes  to  acclereated
atherosclerosis in hypothyroidism; however, this hypothyreoid phase is very short, and readminsitration of T 4
improves endothelials function. NO is the mediator of FMD, and the elevation of NO level was found to be
an  independent  determinant  of  improvement  of  FMD  by  multiplex  regression  analysis. There  was  no
association  between  changes  of  FMD  and  LDL-C;  it  seems  that  T4 therapy  can  improve  the  FMD
independently from the lipid profile.  Endothelial dysfunction is thought to be an important factor in the
development  of  atherosclerosis,  hypertension,  and heart  failure.  The  endothelium is  a  specific  target  of
thyroid  hormones  in  human.  Several  potential  mechanisms  have  been  proposed  to  explain  abnormal
endothelial function. Endothelial cells contain nuclear T3 receptors, endothelium dependent vasodilatation is
modulated by T3. It has been also shown that thyroid hormones cause rapid relaxation of vascular smooth
muscle cells isolated from rat. Patients with subclinical hypothyroidism were shown to develop endothelium
dysfunction  resulting  from  a  reduction  in  NO  availability,  an  alteration  partially  independent  of  lipid
changes,  and  reversed  by  T4 supplementation.  Elevated  ADMA  levels  in  hypothyroidism  and  in
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hyperthyroidism  may  affect  the  maintenance  of  vascular  function  and  integrity  through  inhibiting  NO
synthase that is responsible of NO production. 
Aortic  stiffness  and  diastolic  heart  function  were  worse  in  both  hypothyroidism  and  subclinical
hyperthyroidism compared to controls, and subclinical hyperthyrodism was more disadvantageous in this
respect. T4 was an independent factor associated in a positive manner with aortic stiffness. Only few data are
available  on  aortic  stiffness  in  hyperthyroidism.  Sympathetic  activation  increases  arterial  wall  stiffness.
Manifestations of hyperthyroidism resemble the effect of cathecholamine excess: the sensitivity of resistance
vessels to the vasoconstrictive action of norepinephrine is enhanced . β1-adrenergic blockade was associated
with  normalization  of  total  arterial  stiffness.  Vascular  inflammation  causes  degradation  of  collagen and
elastin,  evokes  changes  in  the  proteoglycan  composition  and  hydration  status,  and  results  in  medial
calcification leading to increased arterial stiffness. Low-grade inflammation caused endothelial dysfunction
and  impaired  NO  availability  in  patients  with  subclinical  hypothyroidism.  Thyroid  hormone  reduces
systemic  vascular  resistance  and  causes  activation  the  renin-angiotensin-aldosteron  system.  T 3 directly
stimulates the synthesis of renin substrate in the liver. Consequevent sodium reabsorption, increased blood
volume  and  preload  contribute  to  the  characteristic  increase  in  cardiac  output.  Chronic  hemodynamic
overload  causes  increased  myocardial  contractility,  cardiac  hypertrophy,  increased  left-ventricular  mass;
contractile protein synthesis is increased. The faster heart rate in hyperthyroidism result an earlier return of
the forward pressure wave in systole, resulting in a greater overlapping in the forward and reflected pressure
waves.  It  has  been suggested in  earlier  studies that  diastolic dysfunction in subclinical  hyperthyroidism
resulted from increased LVM. However, no significant increases in LVM was found either by us or by other
groups. Dörr et al. showed that  decreased serum TSH levels were not associated with an elevated risk of left
ventricular  hypertrophy,  but  overt  hyperthyrodism  is  an  independent  risk  factor  for  left  ventricular
hypertrophy. Thyroid hormones influence calcium regulation in myocytes, such as increase Ca++-ATPase
activity and decrease phospholamban expression, and increase Ca-influx. Increase in intracellular calcium
may be cause of mediated diastolic  stiffness in hyperthyroid rats heart. 
We detected only slight  impairement  in  aortic  stiffness  and diastolic  function in  acute  short-term
hypothyroidism. Aortic stiffness is likely related to myxoedema of the arterial wall. However, our data do not
support this notion and are consonant with the findings of other studies, hat argued against the role of LDL-C
in  increased  aortic  stiffness.  Impaired  diastolic  function  in  hypopthyroidism  due  to  slow  myocardial
relaxation  results  from  altered  intracellular  calcium  handling,  decreased  activity  of  the  sarcoplasmatic
reticulum  calcium  ATPase  and  /or  increased  expression  of  phospholamban.  Myofibrill  swelling,
mucopolysaccharides accummlation can be detected in hypothyroid heart.
Another  important  consequence of  the  present  investigation was that  thyroxin  induced subclinical
hyperthyroidism evoked a distinct pattern of alteration in the coagulation system: fibrinogen and vWF, the
hemostatic factors associated with cardiovascular risk, were significantly higher in patients on T 4 suppressive
therapy. However, it should be noted that the higher vWF remained within the normal range and fibrinogen
exceeded it  only slightly.  This  observation,  however,  does  not  necessarily  imply  a  lack  of  a  biological
component. Our findings also suggest that improvement in FMD is associated with the increase in serum
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vWF and fibrinogen levels. In subclinical hyperthyroidism a prothrombotic profile has been described: in
thyroidectomized  thyroid  cancer  patients,  while  taking  L-T4,  higher  factor  VIII,  plasminogen  activator
inhibitor (PAI-1), fibrinogen and lower protein C levels were found. These changes may be associated with
hypercoagulability. In  the  majority  of  the  studies,  hypothyroidism  represented  a  hypocoagulable  state.
Decreased platelet adhesiveness, abnormal bleeding time, decreased level of factors VIII, IX, X, and low
vWF activity have been described in these patients. Decreases in the coagulation factors in hypothyroidism
could be explained by the generalized reduction of protein synthesis. In a recent study, a direct stimulatory
effect  of  T3 on fibrinogen synthesis has been observed.  However,  most  recent  studies have suggested a
hypercoagulable state in hypothyroidism with low fibrinolytic activity. Our data partly support the results of
previous studies concerning a prothrombotic biochemical milieu evoked by subclinical hyperthyroidism. 
In  hypothyroidism,  atherogen  lipid  profile  and  higher  homocystein  levels  as  the  well  known
cardiovascularis risk factors were found. In both subclinical hypertyroidism and overt hypothyroidism, we
deteceted low-grade inflammation as shown by the CRP levels; this may further predispose the patients to
atherosclerosis.
These changes were accompanied by a remarkable improvement of endothelial function, and elevation
of nitric oxide concentration. From the viewpoint of atherosclerosis and fatal or non-fatal cardiovascular
events, the L-T4 induced iatrogenic subclinical hyperthyroidism is associated with a slight but long lasting
thyrotoxic  state,  better  endothelial  function (as  characterized by FMD and NO) while  slightly impaired
vascular  injury  markers  (higher  vWF  and  fibrinogen)  and  inflammatory  status  (CRP)  in  subclinical
hyperthyroidism. We conclude that these apparently opposing mechanisms may compensate for each other at
the level of the vessel wall.
In conclusion, our results show that long-term TSH-suppressive T4 therapy has both advantageous
and disadvantageous effects at the level of the vessel wall. These opposite effects may compensate each other
limiting the harmful effect of T4 on vessel wall. Thyroxin withdrawal, even as short as 4 weeks, has several
adverse effects on the heart and the vessel wall. We speculate that four weeks are not enough to develop the
entire  spectrum  of  effects  of  hypothyroidism  on  peripheral  tissues.  As  subclinical  hyperthyroidism  is
sustained for  decades  in  these patients,  the  undesirable  changes caused by this  condition may be more
important in DTC patients.  The degree of TSH suppression in patients with DTC should be kept at the
possible  minimum,  considering  the  potential  benefits  and risks  of  treatment,  especially  in  patients  with
cardiovascular comorbidities, in agreement with the current international recommendations.
6. SUMMARY
DTC is the most frequent endocrine tumor, the prognosis of which is very good with adequate therapy
(operation, radiiodine ablation and T4  suppressive therapy). The purpose of T4 treatment is not only thyroid
hormon substitution after  total  thyroidectomy,  but  to block the TSH-dependent  tumor progression.  TSH
stimulated serum Tg level via T4 withdrawal is the most important part of yearly follow up of patients with
DTC. 
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The aim of this study was to investigate endothelial function together with NO, aortic stiffness, left
ventricular  systolic and diastolic functions,  metabolic parameters and hemostatic factors in patients with
DTC while on TSH suppressive doses of T4, as well as after 4 weeks of T4 withdrawal, in order to assess the
cardiovascular impact of both long-term subclinical hyperthyroidism and short-term hypothyroidism. 
In subclinical hyperthyroidism both FMD and NO were markedly higher and lipid profile was better
than in hypothyroidism. Aortic stiffness and diastolic function were unfavorable both in hypothyroidism and
subclinical hyperthyroidism vs. controls, and subclinical hyperthyroidism was found to exert a more marked
adverse effect on these factors. Fibrinogen and vWF, the hemostasis factors associated with cardiovascular
risk, were significantly higher in subclinical hyperthyroidism. In hypothyroidism, an atherogen lipid profile
and higher  homocystein level  were found.  We deteceted low-grade inflammation by CRP level  in  both
subclinical hypertyroidism and hypothyroidism, which may predispose to atherosclerosis. 
In conclusion, our results confirm that both long-term TSH suppressive T4 therapy and consequent
subclinical hyperthyroidism and  hypothyroidism resulting from thyroxin withdrawal have several adverse
effects on the heart and vessel wall. The degree of TSH suppression in patients with DTC should be kept at
the possible minimum, based on individually determined potential benefits and risks of treatment, especially
in patients with cardiovascular comorbidities.
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